To know more about our studies, visit our SPUR Research website. 


The aim of this study was to explore the validity of the SPUR™ tool as a holistic Patient-Reported Outcome Measure of medication adherence in Chronic Obstructive Pulmonary Disease (COPD). The study has been published in Patient Preference and Adherence. 

The 2 key outputs to keep in mind

  • The predictive validity of SPUR™ to measure adherence of chronic patients living with COPD is confirmed.
  • SPUR™ score is correlated with CAT (COPD Assessment Test) and can identify worsening symptom severity.


100 adult patients suffering from COPD from a large London NHS Trust with at least 1 inhaler prescribed for a minimum of 6 months prior to the study were surveyed.

Patients provided demographic and health-related information and filled out the following questionnaires:

  • SPUR™
  • Validated PROMs measuring adherence
    o The Inhaler Adherence Scale (IAS)
    o The Medication Possession Ratio (MPR)
  • Symptom severity assessment tool:
    o The COPD Assessment Test (CAT)

Spearman’s rank correlation coefficient was calculated to examine correlations between the various PROMs and SPUR.
A Chi-square analysis was conducted to explore the relationship between the CAT and SPUR.


SPUR™ score is correlated with established Patient-Reported Outcomes (PROMs) in this study. Its predictive validity to measure medication adherence in COPD is confirmed.

SPUR™ is also significantly associated to COPD symptom severity. This finding could be applied in clinical practice to prospectively address patient outcomes linked to poor medication adherence.

Read the publication


Please fill in the form to continue reading :


We are processing this data per your request only. We are hosting the data internally. We will not share it.

This data will be used to send you the requested content and other types of content on related topics and will be kept for a maximum of 3 years.

Here’s a link to our privacy policy. You can find out how to send a request to access your data, request to delete your data, correct any inaccuracies or restrict our processing of your data.

You have the right to lodge a complaint about the way we handle your data with French Data Protection authority CNIL or you can contact our DPO at contact form for more information or with concerns.


See also

Scientific communications

A multiple-cohort analysis of the SPUR 6/24 patient-reported adherence tool


Clinical Ink and Observia: Pioneering Personalized Patient Engagement in Clinical Trials


By your side in 2024: Happy Holidays from Observia!

Accès plateformes